ALBIREO PHARMA,INC. (NASDAQ:ALBO) Files An 8-K Results of Operations and Financial Condition

ALBIREO PHARMA,INC. (NASDAQ:ALBO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On March7, 2019, Albireo Pharma,Inc. issued a press release announcing its financial results for the fourth quarter and year ended December31, 2018. The full text of the press release is furnished as Exhibit99.1 to this Current Report on Form8-K.

The information in this Current Report on Form8-K (including Exhibit99.1) shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished with this report:

ExhibitNumber

Description

99.1

Press release dated March7, 2019

ALBIREO PHARMA, INC. Exhibit
EX-99.1 2 a19-4982_3ex99d1.htm EX-99.1 Exhibit 99.1     Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update   – A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early’20 topline readout – – Plan to initiate second A4250 pivotal program in biliary atresia – – Plan to initiate Phase 2 study with elobixibat in NASH – – Management to host conference call and webcast today at 8:30 a.m. EST –   BOSTON — March 7,…
To view the full exhibit click here

An ad to help with our costs